Compare GameStop Corp. (GME) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Novo Nordisk A/S — how do they compare? GameStop Corp. trades at $26.56 (market cap $12.75B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 13× GameStop Corp.'s market cap, and Novo Nordisk A/S pays a 4.71% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Novo Nordisk A/S for 116 Days on average.
| GME | NVO | |
|---|---|---|
Market Cap | $12.75B | $165.31B |
Volume | 13,026,993 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.56 | $63.98 |
52-Week Low | $17.87 | $35.29 |
Typical Hold Time | 62 Days | 116 Days |
Enterprise Value | $12.03B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $25.28, up 2.85% today, with a bullish technical signal from moving averages and strong insider buying by CEO Ryan Cohen. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, and holds a robust cash position of $4.77 billion. Recent earnings beat expectations in two of the last three quarters, though revenue has declined from $6.0 billion in 2022 to $3.8 billion in 2025.
The outlook is mixed: strong cash reserves and insider confidence support upside, but declining revenue and a high P/E ratio of 16.63 pose risks. Analyst consensus is cautious with only 16.67% buy ratings. Key risks include execution challenges in the retail sector and reliance on insider sentiment rather than fundamental growth.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
